Boston Scientific Corporation BSX

Key data

The business

Boston Scientific makes the tools that go inside the body to fix it without open surgery. Its biggest business is cardiovascular: catheters, stents, heart-valve repair, the Watchman implant the size of a quarter that plugs a pocket in the heart to prevent strokes, and, the growth engine, Farapulse, a pulsed-field ablation catheter that a cardiologist threads up to the heart and pulses to silence the misfiring tissue behind atrial fibrillation. The rest is MedSurg: scopes for the gut, stone-removal tools for kidneys, nerve stimulators for chronic pain. Roughly half of sales are in the United States, the rest spread across Europe, Asia and Latin America. The moat is switching cost layered on know-how: once an electrophysiologist trains on Farapulse and the hospital buys the console it runs on, the next hundred procedures follow the installed base, and the clinical-trial evidence behind pulsed-field ablation is years and hundreds of millions of dollars deep. The company keeps buying smaller innovators, Nalu, SoniVie, Bolt, to restock the pipeline.

The numbers

The record is a decade of compounding that only recently lost a step. Five quarters, oldest to newest:

Revenue climbed every quarter to a record $5.44B, but the year-over-year rate cooled from double digits toward high single digits, the deceleration that took the stock from $109 to $48. Gross margin held near 71%, so the slowdown is volume and mix, not price. The Q1 2026 diluted EPS of $0.90 is flattered by a one-time tax benefit; strip it and quarterly earnings power sits nearer $0.60. On the company's adjusted measure it has now topped analyst estimates four quarters running, $0.86 against $0.835 last quarter.

Over five years the compounding is real: revenue up from $11.9B to $20.1B, a 14% annual clip, while operating margin widened from 10% to 18%.

Diluted EPS nearly tripled across the span. That is the tension. Consensus now prices barely 6% annual revenue growth through 2028, against the 14% just delivered. At $47.80 you pay about 19 times trailing GAAP earnings, closer to 15 times the adjusted number the company reports, and under 13 times the 2028 estimate. That is the 17th percentile of its own twelve-year multiple range and less than half the roughly 38 times peers command. What this memo believes the market does not: the deceleration is real but overpriced, because Farapulse and Watchman are multi-year adoption curves, not a spent force, and the number that settles it is the next organic-growth rate stripped of the cyberattack.

Management

Management is putting cash where the story is. In the last twelve months insiders bought $10.0M of stock across ten open-market purchases and sold nothing; CEO Michael Mahoney alone bought $9.0M at about $47 on August 3, an open-market purchase and not a scheduled sale, and director Edward Ludwig added twice. The company also repurchased $2.0B of stock in May, its first buyback of size in years, at prices above today's, a mild ding on timing but a real return of capital. Pay leans on operating targets the margin record has met, and the acquisition cadence has grown earnings without wrecking the balance sheet: net debt runs about 2.1 times EBITDA, interest covered a dozen times over. Mahoney's guidance has generally proven conservative, hence the four straight beats.

How it fails or surprises you

Growth settles at the market's number (downside). Reported YoY revenue already slid from 11.6% to 7.5% in two quarters, and consensus sees about 6% a year through 2028. If Farapulse adoption plateaus as Medtronic's and J&J's pulsed-field systems ramp through 2027, underlying growth holds high-single-digit and 19x trailing earnings is fair, not cheap. The tell is the organic rate once the cyberattack clears.

The cyberattack spreads (downside). The August 26 breach hit the systems that process and ship orders, and the company says both the restoration timeline and the financial impact are still unknown. A dent confined to Q3 is noise; one that drags into Q4 turns a lost quarter into a lost half. If Q3 organic growth lands below the roughly 3% it guided, the breach is worse than framed. That watch-item is still open: Q3 has not been reported.

The re-rating (right tail). At the 17th percentile of its own twelve-year multiple and half what peers fetch, the stock is priced as if growth is broken. If Farapulse and Watchman keep compounding double digits and margins keep widening, a partial re-rate toward 25 times on a mid-teens adjusted-EPS base is a large move, and nobody is paying for it today. The CEO's $9M purchase says he sees it.

Closing thoughts

The next earnings report, due late October, tells you most of what matters: whether underlying demand outside the cyberattack still runs double digit, and whether the hack was one quarter or three. The argument does not smolder for years, it gets answered on one date. The left tail, a structural slowdown to 6% compounded by a lingering breach, is real and is what took two-thirds off the multiple. The right tail, intact double-digit adoption re-rating a stock at the bottom of its own range, is worth more, and the balance sheet plus $9M of insider buying make the downside survivable while you wait. Odds are judgment, not arithmetic: the fatter tail looks like the upside, with the cyberattack the thing that could make that wrong in the near term.

The bet is still that Boston Scientific keeps selling more heart devices every year, above all the Farapulse catheter, that growth stays fast even as Medtronic and Johnson & Johnson push rival versions, and that the hackers are a one-quarter problem, not a lasting one. What breaks it is the pair to watch: Q3 organic growth against the roughly 3% guided, and the normalized rate once the hack clears. If organic growth outside the breach lands below high-single-digit, the deceleration is not finished and neither is the de-rating; if it holds double digit, the market mispriced a compounder for a stumble.